23.83

0.13% -0.03

After Hours: 23.87 0.04 +0.17%

Dianthus Therapeutics Inc (DNTH)

Overview News Price History Financials Discussions Forecast

Dianthus Therapeutics Inc stock is traded at $23.83, with a volume of 183.12K. It is down -0.13% in the last 24 hours and down -14.00% over the past month. Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Previous Close:

$23.86

Open:

$23.81

24h Volume:

183.12K

Relative Volume:

0.76

Market Cap:

$706.18M

Revenue:

$4.12M

Net Income/Loss:

$-56.68M

P/E Ratio:

EPS:

Net Cash Flow:

$-51.44M

1W Performance:

+14.73%

1M Performance:

-14.00%

6M Performance:

+5.68%

1Y Performance:

+111.45%

1-Day Range:

$23.07

$23.99

1-Week Range:

$19.84

$24.30

52-Week Range:

$6.58

$33.77

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name

Dianthus Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

857-201-2700

Address

300 TECHNOLOGY SQUARE, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

DNTH's Discussions on Twitter

Compare DNTH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNTH Dianthus Therapeutics Inc	23.83	706.18M	4.12M	-56.68M	-51.44M	0.00
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-26-24	Initiated	Robert W. Baird	Outperform
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy
Feb-15-24	Initiated	Stifel	Buy
Dec-26-23	Initiated	Jefferies	Buy
Nov-22-23	Initiated	Wedbush	Outperform
Oct-30-23	Initiated	Guggenheim	Buy
Sep-28-23	Initiated	Raymond James	Outperform
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-06-22	Upgrade	Goldman	Neutral → Buy
Aug-20-21	Resumed	Goldman	Neutral
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-21	Reiterated	B. Riley Securities	Buy
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight
Jun-15-21	Initiated	BTIG Research	Buy
May-18-21	Initiated	B. Riley Securities	Buy
Jan-07-21	Initiated	Mizuho	Buy
Jun-08-20	Upgrade	Goldman	Neutral → Buy
Mar-25-19	Downgrade	Goldman	Buy → Neutral
Mar-15-19	Initiated	Raymond James	Outperform

View All

Dianthus Therapeutics Inc Stock (DNTH) Latest News

Nov 27, 2024

Great Point Partners LLC Has $7.53 Million Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Nov 27, 2024

Nov 23, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5.1%What's Next? - MarketBeat

Nov 23, 2024

Nov 20, 2024